Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM01 and Azacitidine in AML and MDS
NCT05140811Phase 2Unknown
- Sponsor
- ImmuneOnco
- Start
- Jan 2022
- Primary completion
- Feb 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of timdarpacept in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by ImmuneOnco. Status: unknown.
02
Drugs
timdarpacept
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05140811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05140811.